BI
REGN icon

Boulegeris Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Boulegeris Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-950
Closed -$328K – 40
2018
Q2 		$328K Buy
950
+80
+9% +$25K 0.16% 47
2018
Q1 		$300K Sell
870
-30
-3% -$10.4K 0.16% 47
2017
Q4 		$338K Sell
900
-5
-0.6% -$2.02K 0.18% 44
2017
Q3 		$405K Buy
905
+10
+1% +$4.76K 0.23% 43
2017
Q2 		$440K Hold
895
– – 0.25% 41
2017
Q1 		$347K Sell
895
-675
-43% -$250K 0.21% 41
2016
Q4 		$576K Sell
1,570
-145
-8% -$55.1K 0.35% 35
2016
Q3 		$689K Buy
1,715
+130
+8% +$52.1K 0.44% 35
2016
Q2 		$554K Buy
1,585
+230
+17% +$88.6K 0.38% 35
2016
Q1 		$488K Buy
1,355
+680
+101% +$280K 0.34% 36
2015
Q4 		$366K Buy
675
+105
+18% +$56.9K 0.27% 38
2015
Q3 		$265K Buy
+570
New +$306K 0.2% 42

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boulegeris Investments's REGN Position: Q3 2018 in Review

Boulegeris Investments sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 950 shares — an estimated $328K sold.

Boulegeris Investments first reported a position in REGN in Q3 2015 and held it in 12 quarters. The position peaked at $689K in Q3 2016. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

  • Boulegeris Investments reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Boulegeris Investments sold 950 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $328K.
  • Boulegeris Investments first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 12 quarters.
  • Boulegeris Investments's Regeneron Pharmaceuticals position peaked at $689K in Q3 2016.
  • 644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Boulegeris Investments's 13F filing for Q3 2018.